Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chubb Ltd (CB) vs Incyte Corporation (INCY) Price & Performance

Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

Chubb Ltd vs Incyte Corporation — how do they compare? Chubb Ltd trades at $345.1 (market cap $133.90B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Chubb Ltd is far larger — about 5.5× Incyte Corporation's market cap, and Chubb Ltd pays a 1.18% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

CBINCY
Market Cap
$133.90B$24.54B
Sector
FinancialsHealth
52-Week High
$363.50$129.93
52-Week Low
$268.20$81.61
Enterprise Value
$154.74B$20.04B
Dividend Yield
1.18%

Returns comparison

Trailing returns across standard periods

About Chubb Ltd

ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.

Read more on CB

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY